Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects1
Gudmundur Johannsson,
Kerstin Albertsson-Wikland,
on behalf of the Swedish Study Group for Growth Hormone Treatment in
Children2 and
Bengt-Åke Bengtsson
Research Center for Endocrinology and Metabolism (G.J., B.-Å.) and
Pediatric Growth Research Center (K.A.-W.), Sahlgrenska University
Hospital, SE-41345 Goteborg, Sweden
Address all correspondence and requests for reprints to: Gudmundur Johannsson, M.D., Ph.D., Research Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden. E-mail: gudmundur.johannsson{at}medic.gu.se
The need for continuing GH replacement in patients with childhood-onset
GHdeficiency continuing into adulthood has been recognized. The
metabolicconsequences of discontinuing GH in adolescent patients with
childhood-onsetGH deficiency and short stature were examined over a
periodof 2 yr. Forty adolescents (aged 1621 yr) receiving GH
treatmentfor more than 3 yr and 16 closely matched healthy controls
werestudied. After a baseline visit, GH treatment was discontinued.
Thepatients were then examined with the same protocol once a yearfor
2 yr. Twenty-one patients had severe GH deficiency (GHD)into
adulthood, whereas 19 patients were regarded as havingsufficient
endogenous GH secretion (GHS). After 2 yr withoutGH treatment, the
serum insulin-like growth factor I level waslower in GHD than in both
GHS and control subjects. Both beforeand 2 yr after GH treatment was
discontinued, serum concentrationsof total cholesterol (C), low
density lipoprotein C, and apolipoproteinB were higher in the GHD than
in both GHS and control subjects.Serum concentrations of high density
lipoprotein C decreasedin the GHD group and increased in the other 2
study groups.The amount of total body and abdominal fat mass
throughout thestudy and the increment in these masses were more marked
inthe GHD than in the GHS and control subjects when GH treatmentwas
discontinued.
The discontinuation of GH therapy in adolescents with severeGHD
continuing into adulthood results over a period of 2 yrin the
accumulation of important cardiovascular risk factorsthat are
associated with GHD in adults.
This article has been cited by other articles:
H. Holmer, B. Ekman, J. Bjork, C.-H. Nordstom, V. Popovic, A. Siversson, and E.-M. Erfurth Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy
Eur. J. Endocrinol.,
November 1, 2009;
161(5):
671 - 679.
[Abstract][Full Text][PDF]
G S Conway, M Szarras-Czapnik, K Racz, A Keller, P Chanson, M Tauber, M Zacharin, and on behalf of the 1369 GHD to GHDA Transition Study Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency
Eur. J. Endocrinol.,
June 1, 2009;
160(6):
899 - 907.
[Abstract][Full Text][PDF]
N. Moller and J. O. L. Jorgensen Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Endocr. Rev.,
April 1, 2009;
30(2):
152 - 177.
[Abstract][Full Text][PDF]
C. Hoybye, P. Jonsson, J. P Monson, M. Koltowska-Haggstrom, V. Hana, M. Geffner, and R. Abs Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency
Eur. J. Endocrinol.,
November 1, 2007;
157(5):
589 - 596.
[Abstract][Full Text][PDF]
H. Urushihara, S. Fukuhara, S. Tai, S. Morita, and K. Chihara Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult- and childhood-onset Japanese hypopituitary adults with GH deficiency during GH replacement
Eur. J. Endocrinol.,
June 1, 2007;
156(6):
637 - 645.
[Abstract][Full Text][PDF]
S. Radovick and S. DiVall Approach to the Growth Hormone-Deficient Child during Transition to Adulthood
J. Clin. Endocrinol. Metab.,
April 1, 2007;
92(4):
1195 - 1200.
[Abstract][Full Text][PDF]
J. Svensson, G. Johannsson, A. Iranmanesh, K. Albertsson-Wikland, J. D Veldhuis, and B.-A. Bengtsson GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood.
Eur. J. Endocrinol.,
July 1, 2006;
155(1):
91 - 99.
[Abstract][Full Text][PDF]
M. Salerno, V. Esposito, V. Farina, G. Radetti, A. Umbaldo, D. Capalbo, L. Spinelli, S. Muzzica, G. Lombardi, and A. Colao Improvement of Cardiac Performance and Cardiovascular Risk Factors in Children with GH Deficiency after Two Years of GH Replacement Therapy: An Observational, Open, Prospective, Case-Control Study
J. Clin. Endocrinol. Metab.,
April 1, 2006;
91(4):
1288 - 1295.
[Abstract][Full Text][PDF]
R. Lanes, A. Soros, K. Flores, P. Gunczler, E. Carrillo, and J. Bandel Endothelial Function, Carotid Artery Intima-Media Thickness, Epicardial Adipose Tissue, and Left Ventricular Mass and Function in Growth Hormone-Deficient Adolescents: Apparent Effects of Growth Hormone Treatment on These Parameters
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
3978 - 3982.
[Abstract][Full Text][PDF]
N. Mauras, O. H. Pescovitz, V. Allada, M. Messig, M. P. Wajnrajch, B. Lippe, and on behalf of the Transition Study Group Limited Efficacy of Growth Hormone (GH) during Transition of GH-Deficient Patients from Adolescence to Adulthood: A Phase III Multicenter, Double-Blind, Randomized Two-Year Trial
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
3946 - 3955.
[Abstract][Full Text][PDF]
A. Colao, C. Di Somma, F. Rota, S. Di Maio, M. Salerno, A. Klain, S. Spiezia, and G. Lombardi Common Carotid Intima-Media Thickness in Growth Hormone (GH)-Deficient Adolescents: A Prospective Study after GH Withdrawal and Restarting GH Replacement
J. Clin. Endocrinol. Metab.,
May 1, 2005;
90(5):
2659 - 2665.
[Abstract][Full Text][PDF]
C. Franco, J. Brandberg, L. Lonn, B. Andersson, B.-A. Bengtsson, and G. Johannsson Growth Hormone Treatment Reduces Abdominal Visceral Fat in Postmenopausal Women with Abdominal Obesity: A 12-Month Placebo-Controlled Trial
J. Clin. Endocrinol. Metab.,
March 1, 2005;
90(3):
1466 - 1474.
[Abstract][Full Text][PDF]
A. Mukherjee, S. Tolhurst-Cleaver, W. D. J. Ryder, L. Smethurst, and S. M. Shalet The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy
J. Clin. Endocrinol. Metab.,
March 1, 2005;
90(3):
1542 - 1549.
[Abstract][Full Text][PDF]
P E Clayton, R C Cuneo, A Juul, J P Monson, S M Shalet, and M Tauber Consensus statement on the management of the GH-treated adolescent in the transition to adult care
Eur. J. Endocrinol.,
February 1, 2005;
152(2):
165 - 170.
[Abstract][Full Text][PDF]
M. Bohlooly-Y, B. Olsson, C. E.G. Bruder, D. Linden, K. Sjogren, M. Bjursell, E. Egecioglu, L. Svensson, P. Brodin, J. C. Waterton, et al. Growth Hormone Overexpression in the Central Nervous System Results in Hyperphagia-Induced Obesity Associated With Insulin Resistance and Dyslipidemia
Diabetes,
January 1, 2005;
54(1):
51 - 62.
[Abstract][Full Text][PDF]
A. F. Attanasio, E. Shavrikova, W. F. Blum, M. Cromer, C. J. Child, M. Paskova, J. Lebl, J. J. Chipman, the Hypopituitary Developmental Outcome Study Grou, and S. M. Shalet Continued Growth Hormone (GH) Treatment after Final Height Is Necessary to Complete Somatic Development in Childhood-Onset GH-Deficient Patients
J. Clin. Endocrinol. Metab.,
October 1, 2004;
89(10):
4857 - 4862.
[Abstract][Full Text][PDF]
P. V. Carroll, W. M. Drake, K. T. Maher, K. Metcalfe, N. J. Shaw, D. B. Dunger, T. D. Cheetham, C. Camacho-Hubner, M. O. Savage, and J. P. Monson Comparison of Continuation or Cessation of Growth Hormone (GH) Therapy on Body Composition and Metabolic Status in Adolescents with Severe GH Deficiency at Completion of Linear Growth
J. Clin. Endocrinol. Metab.,
August 1, 2004;
89(8):
3890 - 3895.
[Abstract][Full Text][PDF]
J. A.M. de Boer, C. B. Lambalk, H. H. Hendriks, C. van Aken, E. A. van der Veen, and J. Schoemaker Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome
Hum. Reprod.,
March 1, 2004;
19(3):
504 - 509.
[Abstract][Full Text][PDF]
S. G. Albert and A. D. Mooradian Low-Dose Recombinant Human Growth Hormone as Adjuvant Therapy to Lifestyle Modifications in the Management of Obesity
J. Clin. Endocrinol. Metab.,
February 1, 2004;
89(2):
695 - 701.
[Abstract][Full Text][PDF]
M. Tauber, B. Jouret, A. Cartault, N. Lounis, M. Gayrard, C. Marcouyeux, C. Pienkowski, I. Oliver, P. Moulin, P. Otal, et al. Adolescents with Partial Growth Hormone (GH) Deficiency Develop Alterations of Body Composition after GH Discontinuation and Require Follow-Up
J. Clin. Endocrinol. Metab.,
November 1, 2003;
88(11):
5101 - 5106.
[Abstract][Full Text][PDF]
S. M. Shalet, E. Shavrikova, M. Cromer, C. J. Child, E. Keller, J. Zapletalova, T. Moshang, W. F. Blum, J. J. Chipman, C. A. Quigley, et al. Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-Deficient Patients: A 2-Year Randomized, Controlled, Dose-Ranging Study
J. Clin. Endocrinol. Metab.,
September 1, 2003;
88(9):
4124 - 4129.
[Abstract][Full Text][PDF]
Y. van Pareren, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Effect of Discontinuation of Growth Hormone Treatment on Risk Factors for Cardiovascular Disease in Adolescents Born Small for Gestational Age
J. Clin. Endocrinol. Metab.,
January 1, 2003;
88(1):
347 - 353.
[Abstract][Full Text][PDF]
Y. K. van Pareren, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, T. C. J. Sas, and S. L. S. Drop Effect of Discontinuation of Long-Term Growth Hormone Treatment on Carbohydrate Metabolism and Risk Factors for Cardiovascular Disease in Girls with Turner Syndrome
J. Clin. Endocrinol. Metab.,
December 1, 2002;
87(12):
5442 - 5448.
[Abstract][Full Text][PDF]
D. M. Cook Shouldn't Adults with Growth Hormone Deficiency Be Offered Growth Hormone Replacement Therapy?
Ann Intern Med,
August 6, 2002;
137(3):
197 - 201.
[Abstract][Full Text][PDF]
A. Colao, C. Di Somma, M. Salerno, L. Spinelli, F. Orio, and G. Lombardi The Cardiovascular Risk of GH-Deficient Adolescents
J. Clin. Endocrinol. Metab.,
August 1, 2002;
87(8):
3650 - 3655.
[Abstract][Full Text][PDF]
A. F. Attanasio, S. Howell, P. C. Bates, P. Frewer, J. Chipman, W. F. Blum, and S. M. Shalet Body Composition, IGF-I and IGFBP-3 Concentrations as Outcome Measures in Severely GH-Deficient (GHD) Patients after Childhood GH Treatment: A Comparison with Adult Onset GHD Patients
J. Clin. Endocrinol. Metab.,
July 1, 2002;
87(7):
3368 - 3372.
[Abstract][Full Text][PDF]
L. Hulthen, B.-A. Bengtsson, K. S. Sunnerhagen, L. Hallberg, G. Grimby, and G. Johannsson GH Is Needed for the Maturation of Muscle Mass and Strength in Adolescents
J. Clin. Endocrinol. Metab.,
October 1, 2001;
86(10):
4765 - 4770.
[Abstract][Full Text][PDF]
W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children
Endocr. Rev.,
August 1, 2001;
22(4):
425 - 450.
[Abstract][Full Text][PDF]
L. Wiren, G. Johannsson, and B.-A. Bengtsson A Prospective Investigation of Quality of Life and Psychological Well-Being after the Discontinuation of GH Treatment in Adolescent Patients Who Had GH Deficiency during Childhood
J. Clin. Endocrinol. Metab.,
August 1, 2001;
86(8):
3494 - 3498.
[Abstract][Full Text][PDF]
A. M. Ahmad, R. Guzder, A. M. Wallace, J. Thomas, W. D. Fraser, and J. P. Vora Circadian and Ultradian Rhythm and Leptin Pulsatility in Adult GH Deficiency: Effects of GH Replacement
J. Clin. Endocrinol. Metab.,
August 1, 2001;
86(8):
3499 - 3506.
[Abstract][Full Text][PDF]
R. Lanes, P. Gunczler, E. Lopez, S. Esaa, O. Villaroel, and R. Revel-Chion Cardiac Mass and Function, Carotid Artery Intima-Media Thickness, and Lipoprotein Levels in Growth Hormone-Deficient Adolescents
J. Clin. Endocrinol. Metab.,
March 1, 2001;
86(3):
1061 - 1065.
[Abstract][Full Text]